Maria Stefania De Propris

Maria Stefania De Propris

Auto-generated profile, based on publicly available information

Maria Stefania De Propris

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Hematological Oncology
Verified
Journal Article
Open access
LDLivia Donzelli
Livia Donzelli
VZVeronica Zullino
Veronica Zullino
GTGiovanni Fernando Torelli
Giovanni Fernando Torelli
MPMaria Stefania De Propris
Maria Stefania De Propris
MPMario Piazzolla
Mario Piazzolla
ARAlice DI ROCCO
Alice DI ROCCO
Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell‐associated neurotoxicity syndrome (ICANS), immune cell‐associated hematotoxicity (ICAHT), and immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS), which is characterized by a rare and life‐threatening hyperinflammatory response. This paper presents a case of a 56‐year‐old woman with relapsed mantle cell lymphoma (MCL) treated with the CAR‐T cell therapy, brexucabtagene autoleucel, who had subsequently developed CRS and later IEC‐HS. Initial management included tocilizumab, corticosteroids, and anakinra, followed by the compassionate use of emapalumab, an interferon‐γ blocker. To provide broader context, we conducted a literature review of CAR‐T cell‐related toxicities, focusing on IEC‐HS and its management with emapalumab. Clinical and laboratory manifestations, such as elevated ferritin levels, cytopenias, and organ dysfunction, underpin the diagnostic criteria for IEC‐HS. Vigilant monitoring and tailored therapeutic approaches are required to effectively manage toxicities associated with CAR‐T cell therapy, to maximize its benefits and minimize adverse effects. In more severe IEC‐HS cases, emapalumab may be used as an effective targeted therapy.

22 January 2026 in Leukemia
Verified
Journal Article
Closed access
PDF file
MAMichela Ansuinelli
Michela Ansuinelli
NPNadia Peragine
Nadia Peragine
MPMaria Stefania De Propris
Maria Stefania De Propris
MPMaria Cristina Puzzolo
Maria Cristina Puzzolo
MTMariangela Di Trani
Mariangela Di Trani
RFRobin Foà
Robin Foà

28 April 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ALAlessandro Laganà
Alessandro Laganà
DKDeborah Kasmi
Deborah Kasmi
DDDaniela Diverio
Daniela Diverio
MBMaria Laura Bisegna
Maria Laura Bisegna
ICIda Carmosino
Ida Carmosino
MPMaria Stefania De Propris
Maria Stefania De Propris
Internal tandem duplications of FLT3 (FLT3-ITD) in acute myeloid leukemia (AML) are associated with poor outcomes. CD99 is frequently overexpressed in AML and emerged as potential diagnostic marker. Ninety consecutive newly diagnosed AML patients were retrospectively analyzed. Immunophenotypic profiles were correlated with molecular assessment. Patients were categorized into FLT3-ITDmut (28.9%) and FLT3wt (71.1%). CD99 was expressed in 100% of FLT3-ITDmut-AML compared to 48% in FLT3wt cases. FLT3-ITDmut-AML exhibited higher CD99 expression percentage. CD34 expression was lower in FLT3-ITDmut-AML, with a positivity rate of 31% versus 83% in FLT3wt cases. Multivariate analysis confirmed that CD99 positivity (OR 17.67; p = 0.010) and CD34 negativity (OR 10.00; p = 0.039) were independently associated with FLT3-ITDmut-AML. CD99 and CD34 displayed NPVs of 100% and 86.9%, respectively, with moderate PPVs (45.6% and 62.1%) for the diagnosis of FLT3-ITDmut-AML. CD99 is a highly reliable marker in FLT3-ITDmut-AML and its absence virtually excludes the presence of a FLT3-ITD mutation.

1 January 2026 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
ALAlessandro Laganà
Alessandro Laganà
MBMatteo Breccia
Matteo Breccia
LELoredana Elia
Loredana Elia
ESEmilia Scalzulli
Emilia Scalzulli
MBMaria Laura Bisegna
Maria Laura Bisegna
MPMaria Stefania De Propris
Maria Stefania De Propris
The CD56briCD38+ neutrophil subset in peripheral blood (PB) exceeding 2.0% may represent as a highly specific and rapid flow cytometric signature for the early detection of Chronic Myeloid Leukemia (CML).

12 August 2026 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
NPNadia Peragine
Nadia Peragine
MAMichela Ansuinelli
Michela Ansuinelli
GRGiulia Radice
Giulia Radice
MTMariangela Di Trani
Mariangela Di Trani
MPMaria Stefania De Propris
Maria Stefania De Propris
RFRobin Foà
Robin Foà